Clinical Trials Logo
  1. Home
  2. Polymyalgia Rheumatica
  3. NCT04972968

A Study to Evaluate the Change in Disease State and Adverse Events in Adult Participants With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment, Receiving Subcutaneous Injections of ABBV-154 — AIM-PMR  

Polymyalgia Rheumatica Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects With Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid Treatment

Clinical Trial Summary

Polymyalgia rheumatica (PMR) is an inflammatory disease causing shoulder, hip, and neck pain and stiffness, in adults aged 50 years or older. This study evaluates how safe and effective ABBV-154 is in participants with glucocorticoid-dependent PMR. Adverse events and change in disease activity will be assessed. ABBV-154 is an investigational drug being evaluated for the treatment of PMR. Participants will be randomized into 1 of 4 treatment groups or arms, each arm receiving a different treatment. There is a 1 in 4 chance that a participant will be assigned to placebo. Around 160 participants, of at least 50 years of age, with PMR will be enrolled in the study at approximately 95 sites worldwide. The study is compromised of a 52 week double-blind, placebo-controlled period and a follow-up visit 70 days after the last dose of the study drug. All participants will receive a glucocorticoid taper along with the assigned dose of ABBV-154 or placebo, subcutaneously (SC) every other week (eow). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04972968
Study type Interventional
Source AbbVie
Contact
Status Terminated
Phase Phase 2
Start date September 9, 2021
Completion date July 24, 2023
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04519580 - Improved Diagnostics and Monitoring of Polymyalgia Rheumatica
Recruiting NCT06460142 - Assessing Biomarker in Giant Cell Arteritis and Polymyalgia Rheumatic
Terminated NCT03600818 - Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica Phase 3
Completed NCT00836810 - Timed Release Tablet Prednisone in Polymyalgia Rheumatica Phase 2/Phase 3
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT03263715 - A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Phase 3
Recruiting NCT05935709 - DANIsh VASculitis Database (DANIVAS)
Not yet recruiting NCT02985424 - Polymyalgia Rheumatica and Giant Cell Arteritis N/A
Completed NCT00138983 - Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Phase 3
Recruiting NCT06130540 - Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR Phase 1
Recruiting NCT05767034 - Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) Phase 3
Terminated NCT01821040 - A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR Phase 3
Recruiting NCT00982332 - Efficacy of Micro-Pulse Steroid Therapy as Induction Therapy in Patients With Polymyalgia Rheumatica N/A
Recruiting NCT05312944 - Polymyalgia Rheumatica Associated to Primary Sjogren Syndrome
Recruiting NCT04664465 - PRediction Of DIverse Glucocorticoids toxIcity OUtcomeS
Withdrawn NCT02899026 - Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica Phase 3
Recruiting NCT03576794 - Treatment With Leflunomide in Patients With Polymyalgia Rheumatica Phase 3
Completed NCT05681676 - Melanocortin Gene Expression in Lymphocytes of Polymyalgia Patients
Recruiting NCT05435781 - Effect of Supplemental Hydrocortisone During Stress in Prednisolone-induced Adrenal Insufficiency Phase 4
Terminated NCT03656627 - Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease Phase 1